ConductScience.org, home

Paper28840010

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L and 7 others. J Thorac Dis, 2017. Cited by 34 papers, by iCite.

Cite this record

ConductScience Library. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. Papers, record 28840010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28840010

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
PubMed
Journal
J Thorac Dis
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
1.52
iCite
Revised in PubMed
2020-09-29
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1D'Ambrosio LLia
2Centis RRosella
3Tiberi SSimon
4Tadolini MMarina
5Dalcolmo MMargareth
6Rendon AAdrian
7Esposito SSusanna
8Migliori GBGiovanni Battista

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117868596First tuberculosis cases in Italy resistant to all tested drugs.Euro Surveill2007https://conductscience.org/library/papers/17868596PubMed
219494215The diarylquinoline TMC207 for multidrug-resistant tuberculosis.N Engl J Med2009https://conductscience.org/library/papers/19494215PubMed
319621072Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med2009https://conductscience.org/library/papers/19621072PubMed
421828024WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.Eur Respir J2011https://conductscience.org/library/papers/21828024PubMed
521885418Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis.Eur Respir J2011https://conductscience.org/library/papers/21885418PubMed
622267754Tuberculosis: cost of illness in Germany.Eur Respir J2012https://conductscience.org/library/papers/22267754PubMed
722379150On linezolid efficacy and tolerability.Eur Respir J2012https://conductscience.org/library/papers/22379150PubMed
822496332Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.Eur Respir J2012https://conductscience.org/library/papers/22496332PubMed
922670901Delamanid for multidrug-resistant pulmonary tuberculosis.N Engl J Med2012https://conductscience.org/library/papers/22670901PubMed
1022997218Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.Eur Respir J2013https://conductscience.org/library/papers/22997218PubMed
1123018916Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.Eur Respir J2013https://conductscience.org/library/papers/23018916PubMed
1223060633Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.Eur Respir J2013https://conductscience.org/library/papers/23060633PubMed
1323075177Linezolid for treatment of chronic extensively drug-resistant tuberculosis.N Engl J Med2012https://conductscience.org/library/papers/23075177PubMed
1423100499Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.Eur Respir J2013https://conductscience.org/library/papers/23100499PubMed
1523813314Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence.Eur Respir J2013https://conductscience.org/library/papers/23813314PubMed
1623949960Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.Eur Respir J2014https://conductscience.org/library/papers/23949960PubMed
1724833763ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.Eur Respir J2014https://conductscience.org/library/papers/24833763PubMed
1825140958Multidrug-resistant tuberculosis and culture conversion with bedaquiline.N Engl J Med2014https://conductscience.org/library/papers/25140958PubMed
1925552734Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.Eur Respir J2015https://conductscience.org/library/papers/25552734PubMed
2025552740Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains.Eur Respir J2015https://conductscience.org/library/papers/25552740PubMed

See all 41 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
41498239Synthesis, Docking, and Biological Studies of Pyrazine Derivatives as Antimycobacterial Agents.Med Chem2025https://conductscience.org/library/papers/41498239PubMed
38420252Multilevel Pre-extensively Drug-resistant Tubercular Spondylodiscitis: Underdiagnosed or Overlooked? A Case Report.J Orthop Case Rep2024https://conductscience.org/library/papers/38420252PubMed
38193667Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/38193667PubMed
37384221Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.Front Cell Infect Microbiol2023https://conductscience.org/library/papers/37384221PubMed
36684898Editorial: Updates on tuberculosis control and management.Front Public Health2022https://conductscience.org/library/papers/36684898PubMed
35458755Synthesis and Antimycobacterial Evaluation of N-(4-(Benzyloxy)benzyl)-4-aminoquinolines.Molecules2022https://conductscience.org/library/papers/35458755PubMed
35404075Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35404075PubMed
35245659Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.Int J Infect Dis2022https://conductscience.org/library/papers/35245659PubMed
35178252Research Questions and Priorities for Pediatric Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses.Tuberc Res Treat2022https://conductscience.org/library/papers/35178252PubMed
34067732Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.Microorganisms2021https://conductscience.org/library/papers/34067732PubMed
31729908Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.Am J Respir Crit Care Med2019https://conductscience.org/library/papers/31729908PubMed
31650321Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.Pharm Res2019https://conductscience.org/library/papers/31650321PubMed
31047750Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections.Bioorg Med Chem Lett2019https://conductscience.org/library/papers/31047750PubMed
31038653International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis.J Bras Pneumol2019https://conductscience.org/library/papers/31038653PubMed
30889995New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents.J Enzyme Inhib Med Chem2019https://conductscience.org/library/papers/30889995PubMed
29933627New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies.Molecules2018https://conductscience.org/library/papers/29933627PubMed
29791553Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy.J Bras Pneumol2018https://conductscience.org/library/papers/29791553PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28840010

GET https://conductscience.org/api/papers/v1/28840010/references?page=2